When dapagliflozin, an SGLT2 inhibitor, was administered to the UNx and sham surgery treatment groups, the onset of hyperglycemia was largely suppressed in both groups, but no significant change in SGLT2 mRNA expression was observed. The gene discussed is SLC5A2; the disease is Hyperglycemia.